Sclafani, F., Rao, S. (2018) Systemic Therapies for Advanced Squamous Cell Anal Cancer. CURRENT ONCOLOGY REPORTS, 20 (7). ISSN 1523-3790

Full text not available from this repository.

Abstract

We aim to summarise the available evidence on systemic therapies for advanced anal cancer. There is no universal consensus on the management of this condition and the prognosis remains poor. Nevertheless, significant progress has been recently made including completion of the first, ever-conducted, randomised trial in the first-line setting, investigation of immunotherapy in the refractory setting and use of comprehensive genomic profiling for a better molecular characterisation of this disease and the identification of novel potential targets. The combination of a platinum agent and a fluoropyrimidine is generally considered the standard first-line treatment. Other cytotoxic agents, especially docetaxel and paclitaxel, have shown activity in both the chemotherapy-naive and chemo-refractory setting and are currently being investigated in clinical trials. Finally, further to the promising results of early clinical trials, immunotherapy with checkpoint inhibitors (i.e. nivolumab and pembrolizumab) is likely to become a standard second-line treatment option.

Item Type:	Review Article
All Authors:	Sclafani, F., Rao, S.
Additional Information:	ISI Document Delivery No.: GH7II Times Cited: 0 Cited Reference Count: 76 Sclafani, Francesco Rao, Sheela National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at The Royal Marsden NHS Foundation Trust; Institute of Cancer Research This work was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research. 0 1 Springer New york 1534-6269
Uncontrolled Keywords:	Advanced anal cancer Systemic therapy Chemotherapy Cisplatin Carboplatin 5-Fluorouracil Capecitabine Paclitaxel Docetaxel Mitomycin Targeted therapy Cetuximab Panitumumab Immunotherapy Pembrolizumab Nivolumab LY2606368 HPV InterAACT Epitopes-HPV02 cetuximab plus chemoradiotherapy metastatic cloacogenic carcinoma single-institution experience cooperative-oncology-group phase-ii 5-fluorouracil chemotherapy epidermoid carcinoma human-papillomavirus immune resistance clinical activity Oncology
Research teams:	Clinical Units > Gastrointestinal Unit
Depositing User:	Barry Jenkins
Date Deposited:	28 Jun 2018 13:05
Last Modified:	28 Jun 2018 13:05
URI:	http://publications.icr.ac.uk/id/eprint/16940

Actions (login required)

View Item